Panelists discuss how AML treatment has entered an exciting era of personalized medicine with increasing oral options and ...

While patients with acute myeloid leukemia (AML) are routinely treated with chemotherapy and other cell-killing therapies, ...

Panelists discuss how the pathophysiology of acute myeloid leukemia has evolved from a single phenotype understanding to recognizing diverse genetic events that lead to transformation at the ...

Promising efficacy and favorable safety data from the Phase 1 study in heavily pre-treated patients show potential of CLN-049 ...

Moleculin Biotech ( (MBRX)) just unveiled an announcement. Moleculin Biotech has revealed promising findings showcasing Annamycin’s potential to combat acute myeloid leukemia (AML) resistant to ...

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute ...

CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily ...

Relapsed acute myeloid leukemia (AML) is when cancer returns after a period of remission. Refractory AML means cancer has not responded to multiple rounds of treatment. Both can affect your treatment ...

The US Acute Myeloid Leukemia Market is poised for continued growth, expected to show a CAGR of $% from 2022 to 2028. The future outlook is characterized by: The ongoing development of targeted ...

Investing.com -- Cullinan Therapeutics (NASDAQ:CGEM) stock surged 16% on Monday after the clinical-stage biopharmaceutical company reported promising clinical data for its leukemia treatment candidate ...

Evaxion Biotech AS (NASDAQ:EVAX) climbed 4.2% in Monday’s premarket session after sharing new preclinical data supporting its ...